Cefpirome versus ceftazidime as empirical sepsis treatment

Diagnostic Microbiology and Infectious Disease

Volumn 31, Issue 3, 1998, Pages 499-500

  Norrby, S Ragnar ^a   Geddes, Alasdair M ^b   Shah, Pramud M ^c  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CEFPIROME; CEFTAZIDIME;

BACTERICIDAL ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE SEVERITY; ENTEROBACTER; GRAM NEGATIVE BACTERIUM; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEPSIS; STAPHYLOCOCCUS AUREUS;

ADULT; CEFTAZIDIME; CEPHALOSPORINS; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; PROGNOSIS; SEPSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0031776934     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(98)00016-9     Document Type: Conference Paper

References (2)

1. TM prognostic system: risk prediction for critically ill hospitalised adults. Chest 100:1619-1636.
2. Spencer R.C. Cross-susceptibility of cefpirome and four other β-lactams against isolates from haematology/oncology intensive-care units. Scand J Infect Dis. Suppl 91:1993;25-32.